ACR Convergence 2025 Conference Preview – Gout Sessions and Posters

Published: October 02, 2025

The American College of Rheumatology (ACR) is holding its annual ACR Convergence conference from October 24 through October 29 in Chicago, Illinois. The six-day conference is largely held in person. The Global Summit will be the only virtual session. However, on-demand recordings are made available to individuals who purchase either an All-Access Pass or the Scientific Sessions Pass. Active learning sessions, networking sessions, and add-on courses are not available virtually.

Registration is now open for individuals interested in attending ACR Convergence 2025.

To help you plan for the conference, we’ve outlined the sessions and poster presentations related to gout that are taking place throughout the six-day conference. The following dates and times are accurate as of October 1, 2025. Consult the official ACR Convergence 2025 online program for the most up-to-date information.

Gout Sessions and Poster Presentations at ACR Convergence 2025

Saturday, October 25

Step-by-Step Guide to Ankle and Foot Ultrasonography: Gout, RA, PsA

7:30 AM – 8:00 AM
Description: This session is part of the Basic Musculoskeletal Ultrasound Course II session that runs from 7:20 AM to 3:05 PM.

Updates in the Diagnosis and Management of Gout

11:10 AM – 11:45 AM
Description: This session is part of the Review Course II session that runs from 10:35 AM to 1:00 PM.

Sunday, October 26

A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/differentiation Factor 15 (GDF-15) Improves Prediction of All-cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Genetics, Genomics & Proteomics Poster session that runs from 10:30 AM to 12:30 PM. Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular mortality which has failed to improve over recent decades, unlike in the general population. Comorbidities and treatment inequity contribute, but underlying gout disease-specific mechanisms may also play a role, since the elevated mortality persists with adjustment for cardiometabolic comorbidities, kidney function, BMI, alcohol, all atherosclerotic cardiovascular risk factors, and serum urate levels. Since detailed characterisation of the plasma proteome can illuminate mechanisms and risk stratification of premature mortality in gout, we leveraged large-scale proteomics data for a nationwide prospective cohort.

A Quality Improvement Project to Explore the Implications of the 2020 ACR Gout Guideline Recommendations for HLA-B5801 Testing

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Measures & Measurement of Healthcare Quality Poster I session that runs from 10:30 AM to 12:30 PM. The presence of the HLA-B5801 allele increases the risk of life-threatening allopurinol hypersensitivity syndrome. The 2020 ACR gout management guidelines conditionally recommend HLA-B5801 testing before starting allopurinol in populations more likely to have this allele, including African Americans and individuals of Southeast Asian descent (FitzGerald et al, Arthritis Care Res 2020). While intended to reduce harm, these guidelines could result in delayed or untreated gout in these high-risk populations if appropriate systems are not in place. This project aims to identify beliefs, practices, and consequences of HLA-B5801 testing to inform future strategies that ensure prompt urate-lowering therapy initiation for all individuals.

Bridging the Gap: Leveraging eConsultation to Improve Access to Quality Gout Care

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Measures & Measurement of Healthcare Quality Poster I session that runs from 10:30 AM to 12:30 PM. In the context of the rheumatology workforce shortage, eConsultation holds significant potential to address some challenges through supporting primary care providers in managing rheumatologic conditions. Gout is a useful prototype for implementation of eConsults considering uric acid as a biomarker, the common nature of gout, and well-defined treatment regimens. This quality improvement project aimed to evaluate the current impact of gout eConsults on improvements in uric acid, consistency of consultation, conversion to in-person visits, and mileage and travel cost savings.

Monday, October 27

The Metabolic Syndrome and Development of Gout

8:00 AM – 8:30 AM
Description: This is the first session that takes place during the Gazing into the Crystal Ball: Gout and Cardiometabolic Comorbidity Management session that runs from 8:00 AM to 9:30 AM.

Cardiovascular Morbidity and Mortality in Gout Patients

8:30 – 9:00 AM
Description: This is the second session that takes place during the Gazing into the Crystal Ball: Gout and Cardiometabolic Comorbidity Management session that runs from 8:00 AM to 9:30 AM.

Treatments of Gout and its Metabolic Risk Factors

9:00 AM – 9:30 AM
Description: This is the third and final session that takes place during the Gazing into the Crystal Ball: Gout and Cardiometabolic Comorbidity Management session that runs from 8:00 AM to 9:30 AM.

Racial and Gender Disparities in Gout Clinical Trials

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Epidemiology & Public Health Poster II session that runs from 10:30 AM to 12:30 PM. To develop effective novel treatment strategies for gout disease that cater to patients from diverse backgrounds, it is crucial that all racial groups, without exception, have equal opportunities to participate in clinical trials. This inclusivity is not just a matter of fairness, but a necessity for the advancement of medical research.

Seasonal Variation in Public Interest in Gout Made More Crystal-Clear: A Longitudinal Infodemiology Study Using Google Trends

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Epidemiology & Public Health Poster II session that runs from 10:30 AM to 12:30 PM. Understanding public interest in gout, as reflected by online behavior, can offer valuable insights into its perception and management. Infodemiology, which examines the distribution and determinants of information on the internet, offers insights into public health trends that are often challenging to capture through traditional epidemiological methods. This approach is especially relevant for analyzing interest patterns over time and across different regions.

Exploring the Role of the Gut Microbiome in Gout: Prospective Analysis of Dietary Fiber Intake and the Risk of Gout

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Epidemiology & Public Health Poster II session that runs from 10:30 AM to 12:30 PM. [Researchers] aimed to prospectively examine whether long-term dietary fiber intake is associated with the risk of gout among women over 34 years of follow-up.

The Care Pathway and Treatment Patterns in Patients with Uncontrolled Gout: A Real-World Survey of Physicians in the United States

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Health Services Research Poster II session. Uncontrolled gout (UG) is a chronic, progressive, and systemic disease characterized by serum uric acid >6 mg/dl and clinical manifestations such as tophi, flares and gouty arthropathy, despite the use of urate lowering therapy. Limited real-world evidence exists on the UG care pathway from diagnosis to long-term management. This study examined the care pathway and treatment patterns of patients with UG in the United States.

Racial Difference in Real-World Use of Urate-Lowering and Adjunctive Therapies for Gout: A 10-Year Propensity-Matched Cohort Study

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Healthcare Disparities in Rheumatology Posters session that runs from 10:30 AM to 12:30 PM. Although achieving target serum urate (SU) and reducing cardiovascular events are cornerstones of gout management, little is known about contemporary treatment patterns across racial and ethnic groups. We compared long-term exposure to urate-lowering therapy, acute-attack medications, procedures, SU, and major adverse cardiovascular events between non-Hispanic White and racial/ethnic minority adults in routine U.S. practice.

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30 AM – 12:30 PM
Description: This poster session features the following posters on gout and gout-related topics. For brevity, the posters have been compiled into the following list:
- Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout
- Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
- Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
- A Quantitative Study of Renal Medulla Echogenicity in 250 Vietnames Gout Patients Shows Correlation with Poor Renal Function
- DDX3X Regulates Gout Inflammation via NLRP3 Inflammasome Activation and Macrophage Pyroptosis Crosstalk
- Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
- Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
- Association Between Leptin Levels, Body Mass Index and Health-related Quality of Life in Patients with Gout
- Association of Walking Volume and Intensity with Incident Gout: A Population-based Cohort Study
- ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations
- Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
- Numerically Reduced but MSU Crystal-Activated NK Cells Promote Osteoclastogenesis in Gout

Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Patient Outcomes, Preferences, & Attitudes Poster II session.

Tuesday, October 28

From Invisibility to Advocacy: A Gout Patient’s Journey to Validation and Systemic Change

9:00 AM – 9:15 AM
Description: This patient perspective session takes place during the Patient Perspectives session that runs from 8:15 AM to 9:30 AM.

Validating the Gouty Arthritis Alleviating Effects of Cerevisterol through Integrated In Silico, In Vitro, and In Vivo Studies

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Osteoarthritis & Joint Biology – Basic Science Poster session which runs from 10:30 AM – 12:30 PM.

Geographic Trends in the Burden of Gout in the United States from 1990 to 2021: A State-level Analysis of Prevalence, Incidence, and Disability

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Epidemiology & Public Health Poster III session that runs from 10:30 AM to 12:30 PM. This study quantifies the long-term trends in gout-related prevalence, incidence, and years lived with disability across all 50 U.S. states from 1990 to 2021.

Seasonal and Racial/Ethnic Variation in Achieving Target Uric Acid Levels in Gout Patients on Urate Lowering Therapy in US Veterans in Central California

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Epidemiology & Public Health Poster III session that runs from 10:30 AM to 12:30 PM. This project examined racial/ethnic and seasonal differences in maintaining target serum uric acid (< 6 mg/dL) among patients on urate-lowering therapy to better understand non-genetic drivers of disease progression.

Twenty-Year Trends in the U.S. Burden of Gout: A State-Level Analysis of Disability and Prevalence from 2001 to 2021

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Epidemiology & Public Health Poster III session that runs from 10:30 AM to 12:30 PM. Using nationally representative data, [researchers] aimed to quantify changes in age-standardized gout-related disability-adjusted life years (DALYs), years lived with disability (YLDs), and prevalence rates between 2001 and 2021, with a focus on regional disparities.

A Real-World Survey on Physicians Perspectives of Uncontrolled Gout and Gout Management Practices

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Health Services Research Poster III session that runs from 10:30 AM – 12:30 PM. An understanding of physician perspectives of gout management across different physician specialties may help to improve education and patient care. This study evaluated physicians' perspectives of uncontrolled gout and gout management practices.

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30 AM – 12:30 PM
Description: This poster session features the following posters on gout and gout-related topics. For brevity, the posters have been compiled into the following list:
- Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data
- Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT
- Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies
- Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
- Value of New PREVENT Calculator in Detecting Cardiovascular Disease in Patients with Gout
- Machine Learning-Based Prediction of Gout Onset in Individuals with Asymptomatic Hyperuricemia Using a Common Data Model
- Innate Transcriptional Response and Control of Expression of the Gout-Associated Colony Stimulating Factor-1 (CSF1) and CSF1 Receptor (CSF1R) Genes to Stimuli
- Characteristics and Management of Gout Patients Under Rheumatologist Care from Low-Income and Middle-Income Asia-Pacific Countries: Data from the APLAR Gout Registry
- Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
- Bone Health in Patients with Gout Using Real-world U.S. Data
- The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study
- Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial
- Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data
- Storytelling and Navigation to Improve Gout Follow-up: A Multicenter, Randomized Controlled Trial
- Characteristics of Gout Flares Over Time with Treat-to-Target Urate-Lowering Therapy Use
- Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)
- A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
- Methods to Address Survival Bias and Competing Risks in Estimating the Causal Risks of Gout on Dementia Risk

Survey of Healthcare Providers’ Knowledge and Attitudes Toward the Management of Uncontrolled Gout

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the Professional Education Poster session which runs from 10:30 AM to 12:30 PM. Although uncontrolled gout (UG) is an inflammatory arthritis triggered by crystallization of monosodium urate within joints following hyperuricemia, increasing evidence supports its classification as a systemic disorder with significant renal implications. Despite this evolving paradigm, UG management remains fragmented across the specialties of rheumatology and nephrology. [Researchers] deployed a survey intended to evaluate rheumatologists’ and nephrologists’ understanding of UG, elucidate their attitudes toward evolving UG management paradigms, and identify barriers to nephrology-led care across specialties.

Management of Uncontrolled Gout Among Rheumatologists: Findings from a Medical Chart Audit

10:30 AM – 12:30 PM
Description: This poster presentation takes place during the ARP Posters II session. Current ACR guidelines recommend a treat-to-target approach with routine sUA monitoring and a sUA goal of < 6mg/dL with the use of urate lowering treatments. The aim of this study was to assess current UG management, treatment practices and perceptions among rheumatologists.

Metabolic & Crystal Arthropathies – Basic & Clinical Science

1:00 PM – 2:30 PM
Description: This poster session features the following posters on gout and gout-related topics. For brevity, the posters have been compiled into the following list:
- The Effect of Prophylactic Colchicine Use on Gene Expression in Gout
- Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials
- Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies
- Multi-omics Integration Reveals Gut Microbiota–Metabolite Dysregulation in Gout with Metabolic Syndrome

Wednesday, October 29

Understanding Gout in Women: Longitudinal Changes in Serum Urate Levels from Pre-menopause Through Post-menopause

12:15 PM – 12:30 PM
Description: This session takes place during the Abstracts: Epidemiology & Public Health I session which runs from 11:30 AM to 1:00 PM. Understanding longitudinal changes in serum urate (SU) allows for the development of evidence-based interventions for gout. Post-menopausal women, who are at risk of gout, have increased SU levels. This increase is partially attributed to the loss of estrogen's protective effect on kidney function. While cross-sectional studies have been conducted, longitudinal SU changes during the menopausal transition and interactions with coexisting conditions that modify SU, such as BMI and estimated glomerular filtration rate (eGFR), are not well studied.